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AbstrACt
Introduction Delirium is frequently observed in the 
intensive care unit (ICU) population, in particular. 
Until today, there is no evidence for any reliable 
pharmacological intervention to treat delirium. The Basel 
BOMP- AID (better Outcome with Melatonin compared to 
Placebo Administered to normalize sleep- wake cycle and 
treat hypoactive ICU Delirium) randomised trial targets 
improvement of hypoactive delirium therapy in critically 
ill patients and will be conducted as a counterpart to 
the Basel ProDex Study (Study Protocol, BMJ Open, July 
2017) on hyperactive and mixed delirium. The aim of the 
BOMP- AID trial is to assess the superiority of melatonin 
to placebo for the treatment of hypoactive delirium in the 
ICU. The study hypothesis is based on the assumption 
that melatonin administered at night restores a normal 
circadian rhythm, and that restoration of a normal 
circadian rhythm will cure delirium.
Methods and analysis The Basel BOMP- AID study is an 
investigator- initiated, single- centre, randomised controlled 
clinical trial for the treatment of hypoactive delirium with 
the once daily oral administration of melatonin 4 mg versus 
placebo in 190 critically ill patients. The primary outcome 
measure is delirium duration in 8- hour shifts. Secondary 
outcome measures include delirium- free days and death 
at 28 days after study inclusion, number of ventilator days, 
length of ICU and hospital stay, and sleep quality. Patients 
will be followed after 3 and 12 months for activities 
of daily living and mortality assessment. Sample size 
was calculated to demonstrate superiority of melatonin 
compared with placebo regarding the duration of delirium. 
Results will be presented using an intention- to- treat 
approach.
Ethics and dissemination This study has been approved 
by the Ethics Committee of Northwestern and Central 
Switzerland and will be conducted in compliance with the 
protocol, the current version of the Declaration of Helsinki, 
the International Conference on Harmonisation (ICH) of 
technical requirements for registration of pharmaceuticals 
for human use; Good Clinical Practice (GCP) or ISO EN 
14155 (as far as applicable), as well as all national 
legal and regulatory requirements. Study results will be 
presented in international conferences and published in a 
peer- reviewed journal.
trial registration number NCT03438526.
Protocol version Clinical Study Protocol Version 3, 
10.03.2019.
strengths and limitations of the study
 ► The study’s main strength is the implementation of 
a promising and secure therapy approach for hypo-
active delirium.
 ► This is a prospective, randomised, double- blind, 
placebo- controlled clinical trial for data of high qual-
ity of evidence.
 ► A competing risk analysis with end of delirium and 
in- hospital death as competing risks will be per-
formed if deaths during delirium are observed.
 ► The study is further limited by the heterogeneity of 
critically ill patients. However, development of dis-
turbed circadian rhythm is considered to develop 
independently of the underlying disease leading to 
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bACkgrOunD AnD rAtIOnAlE
Delirium is a neurobehavioural syndrome that frequently 
develops in the postoperative and/or intensive care 
unit (ICU) setting. The incidence of older patients 
who develop delirium syndrome (further named simply 
‘delirium’) during their hospital stay ranges from 10% 
to 80%.1 2 Cardiac surgery3 and ICU patients4 belong to 
a population with high risk for delirium development. 
Delirium may be accompanied by serious complications 
such as prolonged ICU and hospital stay, reduced quality 
of life and increased mortality. Furthermore, the duration 
of delirium is associated with worse long- term cognitive 
function in the general ICU population.5
The aforementioned consequences of delirium are 
observed in all of three subtypes: hypoactive, hyperac-
tive and mixed. However, pharmacological options to 
manage delirium usually address hyperactive and mixed 
delirium in standard operating procedures targeting 
agitation specifically, whereas pharmacological options to 
favourably influence hypoactive delirium are lacking and 
currently not recommended according to international 
guidelines (eg, American Geriatrics Society, The Amer-
ican Geriatrics Society Expert Panel, JAGS 20156; Pain, 
Agitation/sedation, Delirium, Immobility, and Sleep 
disruption (PADIS) guideline, last update 2018.7
Overall, disturbed circadian rhythm is considered 
to play a crucial role in all three subtypes of delirium,8 
including the hypoactive form.9 Particularly in disorders 
associated with diminished or misaligned melatonin 
rhythms (eg, circadian rhythm‐related sleep disorders, 
jet lag and shiftwork, insomnia in children with neuro-
developmental disorders, Alzheimer’s disease) clinically 
meaningful effects of melatonin treatment have been 
demonstrated in placebo‐controlled trials.10 Previous 
investigations have confirmed loss of circadian rhythm in 
patients who had developed delirium, laying the basis for 
our study hypothesis.11 However, limited evidence of the 
connection between circadian health and delirium was 
found recently in a meta- analysis of 13 trials, but the trials 
investigated were of great heterogeneity.12 The potential 
of chronotherapy to reduce delirium incidence has been 
suggested in a recently published article.13 Moreover, 
melatonin is to be investigated for ICU delirium preven-
tion in an Australian study,14 and a feasibility trial of mela-
tonin for prevention of delirium in critically ill patients 
has just been terminated.15
The Basel BOMP- AID (Better Outcome with Melatonin 
compared to Placebo Administered to normalize sleep- 
wakecycle and treat hypoactive ICU Delirium) prospec-
tive randomised clinical study will investigate if the 
administration of melatonin targeting reinstitution of a 
normal circadian rhythm will lead to shorter duration of 
hypoactive ICU delirium compared with placebo.
The administration of dexmedetomidine compared 
with propofol to treat disturbed circadian rhythm in the 
other two types of delirium—hyperactive and mixed—is 
being investigated in our counterpart study: The Basel 
ProDex clinical study—Comparison of propofol and 
dexmedetomidine infused overnight to treat hyperactive 
and mixed ICU delirium (Study Protocol, BMJ Open, July 
2017).16
HyPOtHEsIs
In our randomised study, we aim to test the hypothesis that 
once daily oral administration of melatonin compared 
with placebo at 20:00 (ie, after completion of scheduled 
nursing procedures, usually around 20:0017), beginning 
at the day of diagnosis of hypoactive delirium may reinsti-
tute normal circadian rhythm thus decreasing the dura-
tion of delirium. It will further be investigated whether 
the improved circadian rhythm might reduce the likeli-
hood of conversion to agitated delirium in patients with 
primary diagnosis of hypoactive delirium. Melatonin/
placebo will be repeated daily until delirium resolution 




The Basel BOMP- AID study is an investigator- initiated, 
single- centre, prospective, randomised, double- blind, 
placebo- controlled clinical trial of patients suffering from 
hypoactive delirium.
Approvals
Approval to conduct this study was granted by the 
Ethics Committee of Northwestern and Central Switzer-
land (EKNZ 2018-00161) in April 2018. This study will 
be registered at the Swiss National Clinical Trial Portal 
(SNCPT) and is registered at  ClinicalTrials. gov (Identi-
fier: NCT03438526).
study setting
Adult ICU at a Swiss academic tertiary medical care centre 
treating medical or surgical patients.
study population
Inclusion criteria
Participants fulfilling all of the following inclusion criteria 
are eligible for the study:
 ► Adult patients (aged 55 years or older).
 ► Current delirium (hypoactive type) detected by a 
specialised assessment method: ICDSC score ≥318 in 
combination with a Richmond Agitation Sedation 
Scale (RASS) score ≤0.
Exclusion criteria
Participants meeting the following criteria are excluded 
from the study:
 – Delirium prior to ICU admission.
 – Sleep disorder not caused by hypoactive delirium.
 – Sedation in the ICU.
 – Hypersensitivity to the studied substances (ie, mela-
tonin, placebo content).
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 – Terminal state.
 – Status epilepticus or postictal states following seizures 
on electroencephalogram (EEG).
 – Active psychosis.




The first oral administration of melatonin at the begin-
ning of the night (20:00) is scheduled at the end of the 
period in which hypoactive delirium is diagnosed (ie, 
24 hours prior first administration of melatonin). Patients 
enrolled in the trial will be randomised to receive either 
melatonin (Circadin, tablets of 2 mg for oral adminis-
tration, Neurim Pharmaceuticals AG, Zug, Switzerland) 
or placebo (lactose monohydrate, cellulose powder, 
magnesium stearate (Ph. Eur.), microcrystalline cellu-
lose, provided by the hospital pharmacy of the University 
Hospital Basel, Switzerland), administered orally at 20:00 
(ground and diluted to change pharmacokinetics from 
slow release to rapid action). The first dose of oral mela-
tonin will be administered after study inclusion (ie, study 
allocation). Rapid melatonin action (ie, high melatonin 
level in a short period of time) corresponds to the phys-
iological path of melatonin regulation within the body.
During the consecutive nights, the randomised study 
drug will be administered again and at the same time if 
indicated. The latter will allow us to clearly detect the 
suggested shortening of delirium duration in the cohort 
receiving melatonin.
After randomisation, the physician in charge will 
prescribe the study drug and the nurse caring for the 
patient will then prepare and administer the study drug 
as prescribed at 20:00 or after the last invasive nursing 
activity:
 ► Melatonin (Circadin): two 2 mg tablets (equals 4 mg 
total in one dose).




Delirium duration in number of 8- hour shifts.
secondary outcome measures
 ► Delirium- free days at 28 days after study inclusion.
 ► Death until day 28, day 90 and day 365 from ICU 
admission.
 ► Number of ventilator days.
 ► Length of ICU stay (hours).
 ► Length of hospital stay (days).
 ► Sleep quality, assessed by the Richards- Campbell Sleep 
Questionnaire (RCSQ; total score).
Other outcome measures
The following outcomes are measured by smartwatches. 
The smartwatches will be attached half an hour before 
the administration of the drug (19:30) and left attached 
as long as possible, but at least until 06:00 of every day of 
the study period. Therefore, the smartwatch will be taken 
off only if the patient can be transferred to the ward or 
during specific procedures (eg, surgery) for hygienic 
reasons.
The following smartwatch assessments are based on 
activity (counts/min):
 ► Sleep duration per night (minutes) defined as the 
period from lights off to lights on.
 ► Number of sleep interruptions (number of consecu-
tive 5 min bouts of >0 activity).
 ► The relative amplitude (RA) calculated from the 
ratio of the most active 10 hours period (M10) to 
the least active 5- hour period (L5) across the aver-
aged 24- hour profile (assessment depends on patient 
cooperation during the day with keeping the smart-
watch attached).
 ► Interdaily stability (IS), which quantifies the invaria-
bility day by day, that is, how well the sleep–wake cycle 
is synchronised to supposedly stable environmental 
cues. Timing information comes from determining 
the onset of the 5 hours with least activity (L5 onset) 
and onset of the 10 hours with most activity (M10 
onset).
In addition, wrist/skin temperature (degrees/min) will 
be registered to assess degree of relaxation (ie, difference 
in degrees Celsius per minute between distal skin regions 
(finger, feet and so on) and proximal skin regions (clavic-
ular, sternum and so on)).
DEfInItIOns/COnDItIOns
Inclusion criteria
Hyperactive delirium presents with restlessness, agitation 
and hypervigilance and is often accompanied by hallu-
cinations and delusions. Patients showing lethargy and 
who seem to be slowed down (eg, speech, spontaneous 
movements) raise suspicion for development of hypo-
active delirium. Mixed delirium shows features of both 
conditions.19
Normally, an ICDSC of ≥4 is warranted to diagnose 
delirium. Due to difficult diagnosis of hypoactive delirium 
and the overlap with mixed delirium, the investigators will 
consider those with an ICDSC score ≥3 (subsyndromal 
delirium, ie, ICDSC=3 in this study20) and Richmond 
Agitation Sedation Scale (RASS) score ≤0 in the absence 
of drug- induced coma as eligible for study inclusion. If 
patients reveal an ICDSC score ≥3 and a RASS score ≤0, a 
member of the study team will assess the patient according 
to The Diagnostic and Statistical Manual of Mental Disor-
ders, Fifth Edition (DSM- V) delirium criteria21 for defi-
nite study inclusion.
Patients suffering from mixed delirium before randomi-
sation (primary diagnosis) will explicitly not be included 
in the study. In case of hyperactivity after the first nightly 
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Exclusion criteria
Sleep disorder not caused by hypoactive delirium
Patients suffering from sleep disorders (eg, restless legs 
syndrome, narcolepsy) or showing signs of sleep disorder 
(eg, insomnia, agitation during the night, sleep fragmen-
tation) will not be included. Known sleep apnoea with or 
without treatment will not lead to study exclusion of the 
patient. Newly diagnosed sleep apnoea or sleep apnoea 
arising under melatonin treatment will lead to study 
exclusion.
Sedation in the ICU
Patients in need of sedation in the ICU will not be 
included. Unsedated patients with diagnosed hypoactive 
delirium will be included also if they are intubated or 
tracheotomised.
Hypersensitivity to the active substances
Hypersensitivity to the active substances is defined as a 
known allergy to melatonin or a substance contained in 
the placebo.
Age <55 years
We will only include patients aged 55 and older in our 
study in accordance with the melatonin instructions for 
intake in Switzerland.
Terminal state
Patients suffering from an incurable disease and who 
have a terminal illness with very short- term life expec-
tancy (48 hours) will not be included in our study.
Status epilepticus or postictal states following seizures on EEG
Patients admitted with status epilepticus or postictal states 
without confirmed resolution of epileptic activity on EEG 
will not be included. An unexplained unconscious state 
will be evaluated with EEG prior to study enrolment. This 
may include a systematic search for other causes (eg, 
hypothyroidism, hypothermia, hypercapnia, opioid over-
dose) including encephalitis.
Active psychosis
Patients with known psychiatric disorder possibly 
revealing psychotic symptoms (eg, schizophrenia) will be 
excluded from the study.
Substance abuse in current medical history
Depending on the substance (ie, benzodiazepines, anti-
psychotics), patients might be excluded during the 
screening procedure. If the study participant raises suspi-
cion for substance withdrawal (eg, completion of patient 
history by next of kin), he or she will be withdrawn from 
the study. Toxicity screening will be performed following 
a case- by- case basis risk assessment.
Dementia
Patients suffering from dementia will not be included.
Pregnancy
Pregnant women will not be included due to lack of data 
for or against melatonin in pregnancy.
Primary outcome measure
Duration of delirium in number of shifts
The onset of delirium will be defined as the start of the 
first of a minimum of two subsequent shifts with an ICDSC 
score ≥3 and a RASS score ≤0. The end of the delirium 
will be defined as the end of the last shift with an ICDSC 
score ≥3 and RASS score ≤0 that precedes a minimum of 
two subsequent shifts with an ICDSC score <3 and RASS 
0 without delirium symptoms according to the DSM- V 
criteria.
On account of its long- time use in our institution and 
its high sensitivity and specificity, as described later, the 
ICDSC represents the preferred assessment tool in our 
study.
secondary outcome measures
Delirium-free days at 28 days after study inclusion
Delirium will be assessed during 28 days after study inclu-
sion if the patient is in the ICU. In case of re- transfer to 
the ICU within this period because of delirium or other 
reasons, delirium of any kind (hypoactive, hyperactive, 
mixed) will be recorded.
Adverse event
An adverse event (AE) is any untoward medical occur-
rence in a patient or a clinical investigation participant 
administered a pharmaceutical product and which does 
not necessarily have a causal relationship with the study 
procedure. An AE can therefore be any unfavourable 
and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with 
the use of a medicinal (investigational) product, whether 
or not related to the medicinal (investigational) product 
(ICH E6 1.2). AEs are therefore difficult to detect in crit-
ically ill patients since the physical state leading to ICU 
admission itself may already lead to severe complications 
and further deterioration of physical and mental health.
serious adverse event
Serious adverse events (SAEs) are classified as any medical 
occurrence that results in death, is life- threatening, 
requires prolongation of existing hospitalisation, or 
results in persistent or significant disability/incapacity. 
SAE reporting is required from the responsible Swiss 
authorities. The third criterion from the SAE defini-
tion will be excluded in our trial, as the occurrence of 
delirium generally leads to prolongation of ICU and/or 
hospital stay.
serious unexpected adverse drug reaction
A serious unexpected adverse drug reaction (SUSAR) 
indicates an adverse drug reaction that is of a nature 
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Table 1 Study period overview
Study period Follow- upEnrolment Allocation Post- allocation Closeout
Time point (hours) –t1 t
0





Vital signs X X X X X
Delirium screening tools X X X X X X
ADLQ X X
Drug therapy
Oral melatonin or placebo X (X) (X) (X)
ADLQ, Activities of Daily Living Questionnaire.
Since melatonin has no known major side effects, no 
AEs/SAEs/SUSARs are expected by its use in delirious 
patients after careful enrolment following our exclusion 
criteria. In addition, much higher doses have been used 
in investigations on melatonin as an anaesthetic adjuvant 
without reported major side effects (animal model).22
stuDy PErIOD OvErvIEw
The study period consists of enrolment, allocation, post- 
allocation and closeout (table 1). Allocation has been 
defined as the first day of melatonin or placebo admin-
istration at 20:00 after delirium has been diagnosed. 
Closeout has been defined as point of time of recovery 
from delirium.
screening
Following the delirium assessment part of the Asses and 
treat pain, Awakening and Breathing trials, Coordina-
tion of care and Choice of sedative, Delirium monitoring 
and management, and Early mobility (ABCDE) bundle23 
representing the core of the institutional Pain, Agitation 
and Delirium (PAD) guidelines,24 we will screen every 
patient admitted to the ICU for ongoing delirium to eval-
uate eligibility for study recruitment.
Delirium assessments
Every patient admitted to the study site will be screened 
for study eligibility according to the inclusion and exclu-
sion criteria. Patients meeting study participation criteria 
are those who fulfil the inclusion criteria and none of the 
exclusion criteria. Eligibility screening data will be stored 
using the electronic case report form (eCRF) established 
by the Clinical Trial Unit (CTU, part of Department of 
Clinical Research), Basel.
For screening and for the whole duration of the 
delirium, we will perform the ICDSC during every shift. 
The ICDSC and the CAM- ICU are the most well- studied 
and widely implemented adult ICU delirium screening 
tools worldwide; both are recommended by regularly 
updated clinical practice guidelines. The Intensive Care 
Unit of the University Hospital Basel routinely uses the 
ICDSC for assessment of delirium. The ICDSC is an 
8- item checklist of delirium symptoms evaluated over an 
8–24 hour period (table 2).25 Detailed information has 
been given in the publication of the study protocol of the 
Basel ProDex Study.16
Nursing interventions
Nursing interventions (eg, position changes; diuresis; 
administration of pain medicine; administration of seda-
tives for nursing procedures and other interventions) will 
be registered.
three-month and 12-month follow-up
To assess long- term follow- up of patients who received 
melatonin and compare it with those who received 
placebo, we will perform a follow- up at 3 and 12 months 
after the prevailing hospital case has been officially closed 
(discharge date). With this follow- up, we will assess the 
following information equally at 3 and 12 months (infor-
mation either given by the patient or his/her family/
contact person):
 ► Death after hospital discharge.
 ► Hospital readmission.
 ► Activities of Daily Living Questionnaire (ADLQ).
 ► Additional episodes of delirium after study closeout.
AssEssMEnts
Assessment of delirium
Delirium will be assessed by the ICDSC as explained 
above.
Assessment of sedation and pain level
Level of sedation will be assessed according to the RASS. 
Pain will be assessed using the Critical Care Pain Obser-
vational Tool (C- POT) and/or Visual Analogue Scale/
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Table 2 Suggestions for assessing delirium with the Intensive Care Delirium Screening Checklist (ICDSC)
1. Altered level of consciousness choose one from A–E
A.  Exaggerated response to normal stimulation RASS=+1 to +4 (1 point)
B.  Normal wakefulness RASS=0 (0 points)
C.  Response to mild or moderate stimulation (follows commands) RASS −1 to −3 (0 points)
D.  Response only to intense and repeated stimulation (eg, loud voice 
and pain)
RASS −4 *Stop assessment
E.  No response RASS −5 *Stop assessment
2. Inattention (1 point if any present)
A.  Difficulty in following commands OR
B.  Easily distracted by external stimuli OR
C.  Difficulty in shifting focus
Does the patient follow you with their eyes?
3. Disorientation (1 point if any abnormality)
A.  Mistake in either time, place or person
Does the patient recognise ICU caregivers who have cared for him/her and not recognise those that have not? What kind of 
place are you in? (list examples)
4. Hallucinations or delusions (1 point if any abnormality)
A.  Equivocal evidence of hallucinations or a behaviour due to hallucinations (Hallucination=perception of something that is 
not there with NO stimulus) OR
B.  Delusions or gross impairment of reality testing (Delusion=false belief that is fixed/unchanging)
Any hallucinations now or over past 24 hours? Are you afraid of the people or things around you? (fear that is inappropriate to 
the clinical situation)
5. Psychomotor agitation or delay (1 point for either)
A.  Hyperactivity requiring the use of additional sedative drugs or restraints in order to control potential danger (eg, pulling out 
IV lines or hitting staff) OR
B.  Hypoactive or clinically noticeable psychomotor slowing or delay
Based on documentation and observation during shift by primary caregiver
6. Inappropriate speech or mood (1 point for either)
A.  Inappropriate, disorganised or incoherent speech OR
B.  Inappropriate mood related to events or situation
Is the patient apathetic to current clinical situation (ie, lack of emotion)? Any gross abnormalities in speech or mood? Is patient 
inappropriately demanding?
7. Sleep/wake cycle disturbance (1 point for any abnormality)
A.  Sleeping less than 4 hours at night OR
B.  Waking frequently at night (does not include wakefulness initiated by medical staff or due to loud environment) OR
C.  Sleep≥4 hours during the day
Based on primary caregiver assessment
8. Symptom fluctuation (1 point for any)
Fluctuation of any of the above items (ie, 1–7) over 24 hours (eg, from one hospital shift to another)
Based on primary caregiver assessment
Total ICSDC score (add 1–8)
ICSDC, Intensive Care Delirium Screening Checklist; ICU, intensive care unit ; RASS, Richmond Agitation Sedation Scale.
All scores (ie, ICDSC, RASS/SAS, CPOT, VAS/NRS) 
will be assessed by nurses responsible for the treatment of 
the study patient. Advanced nurse practitioners coach the 
nursing staff and verify the agitation and delirium assess-
ments in the study patients in regular intervals.
Assessment of study drug side effects
We will not administer melatonin in a dose to exert seda-
tive effects or other potential side effects. The chosen 
dose of 4 mg has been determined after consulting a 
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Assessments documented on the case report form
On our eCRF, we will document the following information 
concerning our study participants (sequential order):
 ► Patient information including socioeconomic status.
 ► Study group.
 ► Study eligibility.
 ► Results of the planned assessment tools.
 ► Cardiovascular parameters.
 ► Laboratory values.
 ► Drugs administered.
 ► Nursing interventions.
 ► Outcome overview.
 ► Follow- up at 3 and 12 months.
rAnDOMIsAtIOn
Trial staff will have permanent access to the eCRF where 
patients are screened and randomised to one of the study 
arms. Randomisation will be performed via the eCRF after 
checking the eligibility of the patient. A unique patient 
identification code will be assigned to every screened 
patient without possible inference to patient identity.
Stratified block randomisation will be performed with 
stratification for type of admission (medical or surgical) 
and sepsis (yes or no).
All patients with hypoactive delirium, except for those 
meeting one or more of the exclusion criteria, will be 
randomised to our study.
blInDIng
The treating medical team (ie, responsible nurse and 
physician) and the patient will be blinded for the treat-
ment arm (placebo vs active comparator). Daily assess-
ment of mental state will be documented by the treating 
medical team. Study allocation/termination and outcome 
assessment including follow- up will be coordinated by a 
member of the study team.
PAtIEnt InfOrMAtIOn AnD InfOrMED COnsEnt
Because all study participants are delirious, they do not 
have the capacity to give their consent for the study. For 
this reason, an independent auditing physician, acting as 
the patient’s representative, will declare each patient’s 
suitability for study participation in the patient’s name. 
The signed document of the independent physician is the 
prevailing condition for inclusion of the patient in our 
study.
If possible, depending on the general condition of the 
delirious participants, the investigators will explain to 
each participant the nature of the study, its purpose, the 
procedures involved, the expected duration, the potential 
risks and benefits, and any discomfort it may entail. Each 
participant (depending on constitution) or their next 
of kin will be informed that participation in the study is 
voluntary, that withdrawal from the study is possible any 
time and that withdrawal of consent will not affect the 
subsequent medical assistance and treatment.
If at all possible, the participant or the next of kin will 
be informed that the medical record may be examined by 
authorised individuals other than their treating physician.
All participants in the study will be provided a partici-
pant information sheet describing the study and providing 
sufficient information for the participant and his/her 
next of kin to make an informed decision about their 
participation in the study. We will also provide a consent 
form to be signed by participant’s next of kin.
The information sheet and the consent forms for 
participants and next of kin have been submitted to 
the competent ethics committee for revision and have 
been approved. The formal consent from a participant’s 
next of kin, using the approved consent form, must be 
obtained before the participant is subjected to any study 
procedure.
The next of kin should read and consider the state-
ment before signing and dating the informed consent 
form, and should be given a copy of the signed docu-
ment. The consent form must also be signed and dated 
by the investigator (or his designee). The signed form will 
be retained as part of the study records. Participant’s for 
whom consent cannot be obtained will be excluded from 
the study.
After recovery, the patient will be informed about his/
her participation in the study and he/she will have the 
possibility to withdraw their data from the study. In case 
of ex- post study withdrawal, patient data will be destroyed 
on the study participant’s wish.
sAfEty
No SAEs are expected to result from the administration 
of melatonin in delirious patients after careful enrolment 
following our exclusion criteria.26 Melatonin appears to 
be safe when used short term.27
An individual subject will be excluded from the study in 
case of the following:
 ► Withdrawal of consent by the independent physician 
or next of kin.
 ► An AE that in the opinion of the sponsor contraindi-
cates further measuring (emergency setting).
serious adverse reactions
The occurrence of SAEs will be assessed during every shift 
based on the bedside visit and results of vital and labora-
tory parameters and will be recorded daily on the eCRF.
All changes in research activity and unanticipated prob-
lems will be reported to the competent Ethics Committee 
by the sponsor and the principal investigator. An SAE or a 
SUSAR must be reported within 7 days if fatal, otherwise 
within 15 days. The sponsor will provide an annual safety 
report.
Melatonin
No serious adverse reactions are specified in the product 
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Figure 1 Total sample size (number of patients, not 
including dropouts) needed to be able to show the superiority 
of melatonin to placebo with respect to delirium duration 
(number of shifts), assuming an SD of 6 shifts, depending 
on the expected effect size. The numbers on the curves 
show the corresponding power. An example is shown for an 
effect size of 3 shifts and a power of 90%. The curves are 
smoothed and for illustration only.
www. compendium. ch). Impact on renal/hepatic impair-
ment has not been investigated.
PAtIEnt wItHDrAwAl
Patients withdrawn (excluding ex- post study withdrawal) 
from the study and subjects who could not be followed 
over the intended period and for all designated points 
of assessments, regardless of reason will be included in 
the intention- to- treat (ITT) analysis. Unless consent for 
follow- up is withdrawn, subjects discontinued before 
closeout will be followed for the full study period, and all 
laboratory and clinical evaluations will occur as defined 
in the protocol. We can guarantee that the measurements 
will by no means delay therapy.
stAtIstICs
Detailed methodology for summaries and statistical anal-
yses of the data collected in this study will be documented 
in a statistical analysis plan, which will be finalised before 
database closure and will be under version control by the 
Clinical Trial Unit, University Hospital of Basel.
Hypothesis
For the primary outcome, the null hypothesis to be tested 
is that ICU patients in a state of hypoactive delirium 
treated with melatonin or placebo do not differ regarding 
the duration of the delirium.
The corresponding alternative hypothesis is that ICU 
patients in a state of hypoactive delirium treated with 
melatonin or placebo will differ regarding the duration 
of the delirium.
Determination of sample size
Sample size was estimated to be able to show the superi-
ority of melatonin compared with placebo regarding the 
duration of delirium (in number of shifts).
The sample size calculation was based on an expected 
duration of delirium of 15 shifts (5 days) for patients 
treated with placebo (in line with findings of Page et 
al,28 a reduction of the duration of delirium by δ=3 shifts 
(1 day), and an SD in both arms of 6 shifts (2 days).
Sample size was calculated with a resampling method. 
Each sample size, n
i=1,…,49
=10,…, 298, was evaluated 
by sampling 999 times n
i
/2 individual patients from a 
normal distribution with a mean of 15 (placebo arm) and 
n
i
/2 with a mean of 12 (melatonin arm), both with an 
SD of 6. In addition, different effect sizes for melatonin 
versus placebo, ranging from 1 to 6 shifts were applied 
to assess the sensitivity of the sample size with regard to 
the expected effect size. Because the number of shifts can 
only be positive negative simulated values (which rarely 
occurred) were replaced by zero. A Wilcoxon rank- sum 
test was used to test for a difference between trial arms. 
Sample size was set to ensure at least 90% power (1–
β=0.9) at a significance level of 5% (α=0.05).
For this study, assuming a difference in duration of 
delirium of 3 shifts and a SD of 6 shifts, 190 patients should 
be recruited to ensure 180 evaluable patients, considering 
a dropout rate of 5%. Figure 1 shows the sensitivity of the 
sample size is with respect to the expected effect size.
Planned analyses
Datasets to be analysed, analysis populations
We will conduct an ITT and a per protocol (PP) analysis.
The ITT set will include all patients randomised to 
melatonin or placebo excluding cases of ex- post study 
withdrawal. According to the ITT principle, patients will 
be analysed according to the randomised treatment.
The PP set will include all patients from the ITT set who 
met the inclusion criteria, did not meet any of the exclu-
sion criteria and did not have a major protocol violation. 
Patients not receiving the randomised treatment will be 
analysed according to the received treatment.
Primary analysis
The primary outcome, duration of the delirium, will be 
compared between trial arms using a generalised linear 
model with duration of delirium as dependent variable. 
Since delirium duration (number of shifts) corresponds 
to a count variable, we will use a Poisson or negative bino-
mial error distribution (depending on the dispersion). 
Type of admission (medical or surgical), sepsis (yes/no) 
and treatment (melatonin vs placebo) will be used as 
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ITT set and is further referred to as the ‘main analysis’. 
We will estimate effect sizes together with 95% CI.
To assess the sensitivity of the result with respect to the 
analysis method used, we will conduct the following sensi-
tivity analyses on the ITT set:
S1—Comparison of trial arms using a Wilcoxon 
rank- sum test (also called Mann- Whitney test).
S2—As the‘main analysis’, but adjusting the treatment 
effect by including additional covariates in the model that 
might also affect the duration of delirium.
S3—If we observe any deaths during delirium, we will 
perform a competing risk analysis with end of delirium 
and in- hospital death as competing risks.
To assess the sensitivity of the result with respect to the 
analysis set used, we will also apply all analyses described 
above (main and sensitivity analyses) to the PP set.
Secondary analyses
Secondary outcomes will be compared between trial 
arms using statistical models with type of admission, 
sepsis and the treatment as explanatory factors. The 
number of delirium free days at day 28 and the number 
of ventilator days (counts) will be analysed by a gener-
alised linear model with Poisson (or quasipoisson) error 
distribution and log link. Hospital and ICU length of 
stay will be analysed as counts using a generalised linear 
model or, in case of deaths during ICU/hospital stay, 
as time to ICU/hospital discharge using a competing 
risk analysis with end of ICU/hospital stay and in- hos-
pital death as competing risks. Mortality within 28, 90 
and 365 days (binary outcome) will be analysed using 
a generalised linear model with binomial error distri-
bution and logit link, or depending on the number of 
deaths, as time to death with a Cox proportional hazards 
model. Sleep quality (total score of the RCSQ will be 
analysed using a linear or a generalised linear model. 
Outcomes listed as ‘other outcomes’ will be analysed 
descriptively.
In addition, the effect of melatonin versus placebo 
on the primary outcome will be compared among the 
following patient subgroups:
 ► Type of admission (surgical vs medical).
 ► Sepsis (yes/no).
 ► Cardiac surgery (yes vs no).
 ► Gender.
 ► Age (>65 years vs <=65 years).
For each subgroup variable, we will use a statistical 
model similar to the one described as the ‘main analysis’, 
including the subgroup variable, the treatment and the 
interaction between subgroup and treatment. A signifi-
cant interaction will indicate that the treatment effect 
differs among subgroups. We will also estimate the treat-
ment effect (with a 95% CI) separately in each subgroup 
to be able to graphically display the separate effect sizes 
together with the overall effect.
The statistical models for the secondary analyses will be 
applied to the ITT and to the PP set.
Deviation(s) from the original statistical plan
If substantial deviations of the analysis as outlined in these 
sections are needed for whatever reason, the protocol 
will be amended. All deviations of the analysis from the 
protocol or from the detailed analysis plan will be listed 
and justified in a separate section of the final statistical 
report.
Handling of missing data and dropouts
Missing values on the primary endpoint will be imputed 
for the ITT analyses. A detailed description of the impu-
tation methods and corresponding sensitivity will be 
specified in the detailed analysis plan. Missing values on 
secondary endpoints will not be imputed (complete case 
analyses).
DAtA rEgIstrAtIOn
Data will be entered into a web- based eCRF established 
by the CTU Basel. Paper case report forms will be used in 
parallel in case of possible technical difficulties.
DAtA HAnDlIng AnD MAnAgEMEnt
All data from this study will be kept within the Investi-
gator Site File, and only the study team will have access. 
In case of a patient’s ex- post denial of study participa-
tion, the data collected will not be used for publication 
involving either the corresponding trial or future trials. 
In such cases, the data will be destroyed. If the patient 
does not disagree, data collected until the time point of 
withdrawal will be used for analysis, but no further data 
will be collected.
All study data will be archived in a designated place on 
our Surgical Intensive Care Unit at the University Hospital 
of Basel for a minimum of 10 years after study termination 
or premature termination of the clinical study. We plan to 
store the data also within an anonymised and password- 
protected eCRF.
MOnItOrIng
We have appointed an experienced study nurse of the 
University Hospital of Basel to be responsible for study 
monitoring focusing on data entry.
The sponsor plans no regular monitoring visits at the 
investigator’s site prior to the start of the study. Moni-
toring will commence with the study initiation visit, 
followed by regular monitoring visits within timeframes 
that will have to be determined and stated above. A 
member of the study team will conduct daily monitoring 
of eCRF performance.
The source data/documents are accessible to monitors, 
and questions are answered during possible monitoring.
EtHICAl justIfICAtIOn
Due to the nature of delirium, patients eligible for 














































































































10 Hollinger A, et al. BMJ Open 2020;10:e034873. doi:10.1136/bmjopen-2019-034873
Open access 
As described above, we will seek the patient’s approval 
for use of collected data for our publication after the 
delirium has resolved.
Delirium is a serious condition calling for immediate 
diagnosis and therapy. Because ICU length of stay is asso-
ciated with patient morbidity and mortality, we chose to 
investigate a therapeutic approach that might reduce the 
duration of delirium, thus, leading to shorter ICU and 
hospital stays.
By achieving our goal, we may positively influence 
patient well- being and enhance satisfaction after severe 
medical conditions and, most importantly, promote a 
reduction in patient morbidity and mortality. This, in 
turn, would have a positive impact on our society and on 
the economy.
EnrOlMEnt
Patients from the Intensive Care Unit of the University 
Hospital of Basel are primarily scheduled for study partic-
ipation. The study is planned to begin in December 2019 
and will continue for a 3- year period.
stuDy MAnAgEMEnt AnD OrgAnIsAtIOn
The study will be organised and managed by the research 
team of the Intensive Care Unit, University Hospital of 
Basel. An experienced study nurse who is not a member 
of the research team will provide monitoring. The CTU 
Basel will ensure the statistical research plan and statis-
tical analysis. An eCRF will be established.
Co- enrolment of study participants in other clinical trials 
is basically allowed but will have to be discussed among 
the competing research teams prior to randomisation.
InsurAnCE
Insurance will be provided by the Sponsor through the 
liability insurance of the University Hospital of Basel.
DAtA sHArIng AnD PublICAtIOn
Study results will be communicated to the individual 
patient when he or she regains capacity to give study 
consent. During the ongoing study and until publica-
tion, there will be no public access to the data. We plan to 
publish the data in an open source major peer- reviewed 
clinical journal.
A public description of the study in German will soon 




This research is not currently supported by any funding 
agency. We have applied for financial support at the 
ICU Research Foundation of the University of Basel 
(submission until December 2019; decision expected 
February 2020).
 ► Study drug/personnel/laboratory will be financed 
by the above- mentioned grant approved by the ICU 
Research Foundation of the University Hospital of 
Basel.
 ► All other drugs used during the study are part of the 
routine treatment of patients with delirium. No addi-
tional costs will arise.
The design and planned conduct of this trial have not 
been and will not be influenced by any funding sources.
DIsCussIOn
study rationale
We hypothesise that oral administration of melatonin 
compared with placebo at the beginning of the night 
(20:00) will lead to a shorter duration and diminished 
severity of delirium. The results of this study may lead to 
better algorithms for the treatment of delirium, which 
could improve clinical care for patients, reduce the 
burden of family members and protect the patient’s long- 
term autonomy and health.
Population
We will include patients admitted to the ICU suffering 
from hypoactive delirium.
Intervention
There is limited but promising evidence that resto-
ration of circadian rhythm by melatonin shortens the 
duration of hypoactive delirium. In our study, we aim 
to confirm the superiority of melatonin over placebo 
for the delirium treatment. Melatonin reveals no known 
frequent side effects. As such, it is an innovative approach 
for a delirium type that until today lacks the possibility of 
drug treatment.
Comparator
Since there is no pharmacological approach for treat-
ment of hypoactive delirium, we have chosen a placebo as 
a comparator to melatonin to be able to truly confirm or 
refute melatonin as an option.
Outcome
Based on the hypothesis that melatonin shortens the 
duration of delirium, we have decided to evaluate the 
duration of delirium in 8- hour shifts.
sample size
As described above, sample size was estimated to be able 
to show the superiority of melatonin compared with 
placebo regarding the duration of delirium in hours.
Perspective
The Basel BOMP- AID study aims to improve quality of 
delirium treatment by implementation of melatonin into 
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study status
The ethics committee granted approval of this study in 
April 2018. Inclusion of first patient planned for April 
2020.
EtHICs AnD DIssEMInAtIOn
This study has been approved by the Ethics Committee 
of Northwestern and Central Switzerland and will be 
conducted in compliance with the protocol, the current 
version of the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation (ICH) of tech-
nical requirements for registration of pharmaceuticals 
for human use; Good Clinical Practice (GCP) or ISO 
EN14155 (as far as applicable), as well as all national 
legal and regulatory requirements. Study results will be 
presented in international conferences and published in 
a peer- reviewed journal.
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